MDMA venture capital report
This article was originally published in The Gray Sheet
Executive Summary
The Medical Device Manufacturers Association and National Venture Capital Association release a joint 1report on protecting the "fragile" med-tech/venture capital landscape. The report, previewed in February, addresses industry concerns about comparative effectiveness research, pending patent reform legislation, reimbursement and the FDA approval process, which have the potential to impede venture capital investment in device start-ups (2"The Gray Sheet" March 2, 2009, p. 14). In 2008, venture capitalists invested just under $3.5 billion in device firms, down from more than $4 billion in 2007, the report notes